TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29855175
Drug: ABT-122 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (120 or 240 mg every week)
Study: 29855175
Drug: ABT-122 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (120 mg every week)
Study: 29855175
Drug: ABT-122 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (240 mg every week)
Study: 24629425
Drug: Afoxolaner (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afoxolaner (oral chewable formulation at a dose of 2.5mg/kg)
Study: 22831890
Drug: Lidocaine/tetracaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine patch (Rapydan)
Study: 22831890
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of lidocaine 1%
Study: 19336497
Drug: 200 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mug extra fine hydrofluoroalkane (HFA) beclometasone dipropionate twice daily
Study: 10506039
Drug: Pentoxifylline 400
Normalized name: pentoxifylline 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline 400 mg taken orally three times daily
Study: 1667755
Drug: Cyclical transdermal
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical transdermal oestradiol 0.05 mg per day
Study: 1667755
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine oestrogens 0.625 mg per day
Study: 7059440
Drug: Commercial slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial slow-release preparation (Slow Lopresor)
Study: 28423145
Drug: Brief Behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Behavioral Therapy (BBT) - 8 to 12 weekly 45-minute sessions delivered by master's-level clinicians.
Study: 24165545
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with adjunctive slow-release dexamethasone implant
Study: 19056646
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (714 mg/d GTP), 6 capsules per day for 3 weeks
Study: 10719615
Drug: Sustained-release capsule
Normalized name: Dilacor 240mg Sustained-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release capsule of UDCA
Study: 10719615
Drug: Immediate-release preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release preparation of UDCA
Study: 1540063
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.9% saline solution
Study: 2881428
Drug: Psychotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy and Drug Treatment
Study: 30088707
Drug: Compound amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound amino acid plus vitamin E
Study: 25419768
Drug: No skin
Normalized name: Aveeno Skin Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: No skin treatment (Control group 3)
Study: 18606965
Drug: Sumatriptan 85
Normalized name: sumatriptan 85 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 85 mg and naproxen sodium 500 mg (sumatriptan/naproxen)
Study: 16015049
Drug: Delayed-release propranolol
Normalized name: propranolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release propranolol (INP) dosed at 10 p.m.
Study: 1683673
Drug: Amoxicillin trihydrate
Normalized name: Amoxicillin Trihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin trihydrate
Study: 6791197
Drug: Ro 11-2465
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 11-2465 (1 mg daily for 3 days, then 3 mg daily for 7 days)
Study: 6791197
Drug: Ro 11-2465
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 11-2465 (after drug withdrawal)
Study: 30902690
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration <10 min from EMS arrival
Study: 30902690
Drug: Epinephrine administration
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine administration ≥10 min from EMS arrival
Study: 25640368
Drug: Prophylactic use
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of JiSaiXin (G‐CSF) 150ug per day for three days after chemotherapy (Group A)
Study: 25640368
Drug: G‐CSF (JiSaiXin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (JiSaiXin) after neutropenia (Group B)
Study: 22067789
Drug: New tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet formulation containing 0.02 mg ethinylestradiol/3 mg drospirenone/0.451 mg levomefolate calcium
Study: 22067789
Drug: Ethinylestradiol/drospirenone tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol/drospirenone tablet
Study: 22067789
Drug: Levomefolate calcium
Normalized name: Levomefolate Calcium
DrugBank: Levomefolic acid (DB11256)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomefolate calcium tablet
Study: 15224204
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment in control clinic for 6 months.
Study: 9675505
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (CBT) with exposure and response prevention
Study: 2696997
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg t.i.d. after 7-10 days
Study: 2696997
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 10 mg diazepam after 3-4 hours
Study: 524315
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight heparin fraction (intravenous injection)
Study: 524315
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin fraction (intravenous injection)
Study: 524315
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin fractions (subcutaneous injection)
Study: 524315
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin injection (general)
Study: 524315
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight heparin (general)
Study: 524315
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (general)
Study: 24216069
Drug: Omega-3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFAs at a dose of 3 g/day for 8 weeks
Study: 12859262
Drug: Isosorbide-5-mononitrate (ISMN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (ISMN), 10 mg
Study: 10609625
Drug: Salmeterol added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol added to low-dose beclomethasone dipropionate therapy
Study: 10609625
Drug: Doubling the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doubling the dose of beclomethasone dipropionate
Study: 8622048
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen for black myeloma patients
Study: 8622048
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen for white myeloma patients
Study: 1941055
Drug: 5FU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU plus low-dose leucovorin
Study: 1941055
Drug: 5FU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU plus high-dose leucovorin
Study: 1941055
Drug: 5FU plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5FU plus high-dose MTX with leucovorin rescue
Study: 27164714
Drug: Rotigotine (1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (1-3 mg/24 h)
Study: 15725351
Drug: CXCL10 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXCL10 and its receptor CXCR3
Study: 2026301
Drug: Intravesical lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical lidocaine gel
Study: 2026301
Drug: Oral emepronium
Normalized name: emepronium
DrugBank: Emepronium (DB13505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral emepronium bromide
Study: 28942715
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 100 mcg
Study: 28942715
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 200 mcg
Study: 28942715
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray 400 mcg
Study: 28942715
Drug: Fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl citrate intravenous 50 mcg
Study: 19308757
Drug: Other determinants
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other determinants (platinum levels, renal function, glutathione transferase genotypes, diabetes mellitus, alcohol use, co-medication)
Study: 1497158
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg IM
Study: 10919528
Drug: Meperidine 1
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1 mg/kg IM
Study: 8974721
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 infusion
Study: 28195950
Drug: Videoconferencing administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Videoconferencing administration of the La Trobe Communication Questionnaire (LCQ)
Study: 28195950
Drug: In-person administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person administration of the La Trobe Communication Questionnaire (LCQ)
Study: 27276842
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg (2 ml) intravenous 60-90 minutes before surgery
Study: 27276842
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml 60-90 minutes before surgery
Study: 23937657
Drug: Cold atmospheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold atmospheric argon plasma treatment for 2 minutes
Study: 23937657
Drug: Placebo (argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (argon gas) treatment for 2 minutes
Study: 21320138
Drug: ADX10059 120
Normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADX10059 120 mg b.d.
Study: 16984929
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of valsartan and captopril
Study: 7662044
Drug: Acamprosate 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 2.0 g/day (high dose group)
Study: 7662044
Drug: Acamprosate 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate 1.3 g/day (low dose group)
Study: 7662044
Drug: Acamprosate groups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate groups (both doses)
Study: 28713032
Drug: Adaptive Disclosure
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Disclosure (AD) therapy
Study: 25312783
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy with Pre + TAC + CTX
Study: 25312783
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy with Pre + TAC + MMF
Study: 25312783
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy with Pre + TAC + LEF
Study: 25312783
Drug: Triple-combination therapy
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-combination therapy with Pre + TAC + CTX/MMF/LEF
Study: 21256669
Drug: Sterile sodium
Normalized name: Sterile Sodium Chloride
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sterile sodium chloride (NaCl) 0.9% solution
Study: 7272177
Drug: Caroxazone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroxazone treatment
Study: 7272177
Drug: Post-treatment (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (after discontinuation of caroxazone)
Study: 29931594
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl 250 mg three times daily
Study: 25295771
Drug: mHealth technology
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth technology with tailored physical activity prescription targeting changes to daily exercise, sedentary behavior, or both
Study: 20453709
Drug: GPO-VIR S7
Normalized name: tick-borne encephalitis purified antigen
DrugBank: Tick-borne encephalitis vaccine (whole virus, inactivated) (DB16611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPO-VIR S7 chewable tablets
Study: 16077744
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with 1.5 g/kg body weight of a standard amino acid
Study: 16077744
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with 1.2 g/kg body weight of a standard amino acid and 0.3 g/kg L-alanine-L-glutamine
Study: 8622024
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m2 and cyclophosphamide 1,250 mg/m2 with filgrastim 5 microG/kg/d
Study: 8622024
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered first
Study: 8622024
Drug: Cyclophosphamide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide administered first
Study: 6130038
Drug: Metoprolol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (150 mg per day)
Study: 30553916
Drug: D2 receptor
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2 receptor antagonists (three different types)
Study: 29598883
Drug: Omega-3 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (1000 mg/day)
Study: 29598883
Drug: Both omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both omega-3 (1000 mg/day) and vitamin D (1000 IU/day)
Study: 24837794
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose (2 initial days of double maintenance dose)
Study: 24837794
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose (most recent maintenance dose)
Study: 19892836
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal in diabetic patients (with and without insulin)
Study: 12035937
Drug: Alprazolam (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.02 mg/kg po at ‐90 min)
Study: 10591421
Drug: Lactose-free (L-)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-free (L-) formula
Study: 10591421
Drug: Standard lactose-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard lactose-containing (L+) formula
Study: 2008006
Drug: Amnioinfusion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioinfusion treatment group (n = 19)
Study: 26955742
Drug: ATP (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP (40 mg/day) for rabbits; ATP (60 mg twice a day) for patients
Study: 20167591
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not currently using intramuscular interferon beta-1a)
Study: 16923824
Drug: Subacromial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subacromial infusion of 0.5% bupivacaine (group 1)
Study: 16923824
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of fentanyl and ketorolac tromethamine (group 2)
Study: 12142199
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group II)
Study: 9466023
Drug: Lidocaine 2%-buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2%-buprenorphine at a rate of 6.3 ml.hr‐1 (2% group, n = 13)
Study: 9466023
Drug: Lidocaine 6%-buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 6%-buprenorphine at a rate of 2.1 ml.hr‐1 (6% group, n = 15)
Study: 31629703
Drug: Ezetimibe (Eze)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (Eze) + statins (simvastatin 10 mg, 20 mg, 40 mg, 80 mg)
Study: 31629703
Drug: Ezetimibe (Eze)
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe (Eze) + atorvastatin (20 mg, 40 mg)
Study: 31629703
Drug: Statin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin monotherapy (simvastatin, atorvastatin)
Study: 27090395
Drug: High-dose resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose resistance training (RT) maintenance intervention
Study: 27090395
Drug: Low-dose resistance
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose resistance training (RT) maintenance intervention
Study: 19198698
Drug: Controlled-release fluvoxamine
Normalized name: fluvoxamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release fluvoxamine (CR)
Study: 19198698
Drug: Immediate-release fluvoxamine
Normalized name: fluvoxamine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release fluvoxamine (IR)
Study: 16807626
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (3 times weekly at 60% of one-repetition maximum, 9 resistance exercises, 3 sets of 15 repetitions each)
Study: 14568830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of KTP and Nd:YAG lasers
Study: 8823230
Drug: Bosentan (oral)
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan (oral) at doses of 3, 10, 30, 100, 300, 600, 1200, and 2400 mg
Study: 8823230
Drug: Bosentan (intravenous)
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan (intravenous) at doses of 10, 50, 250, 500, and 750 mg
Study: 8823230
Drug: Bosentan (oral)
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan (oral)
Study: 8823230
Drug: Bosentan (intravenous)
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan (intravenous)
Study: 7949478
Drug: bath-PUVA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bath-PUVA therapy (30-min baths in 0.0003% 8-MOP aqueous solution, 4 times a week)
Study: 7949478
Drug: oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of 8-MOP
Study: 3280317
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 40 mg three times daily
Study: 3540229
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg three times daily
Study: 31702655
Drug: SIP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIP with concurrent auditory cues (AC condition)
Study: 27341793
Drug: Intervention sites
Normalized name: PAD,BITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention sites with quarterly workplace assessments and offering HIV treatment at OHUs
Study: 23468262
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg bolus of remifentanil
Study: 23468262
Drug: 0.5 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/kg bolus of remifentanil
Study: 21575095
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of differentiated adipocytes
Study: 8846523
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate (5.04 ± 0.60 g daily, 10.1 ± 1.20 tablets of 500 mg)
Study: 8846523
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (2.71 ± 0.48 g daily, 5.4 ± 0.95 capsules of 500 mg) with aluminum hydroxide (0.69 ± 0.27 g daily, 1.4 ± 0.55 tablets of 500 mg)
Study: 27707807
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine
Study: 6742382
Drug: prilocaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: prilocaine 0.5% with octapressin 0.03 iu per ml
Study: 26266260
Drug: Vaginal Zataria
Normalized name: Saiga tatarica horn extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Zataria multiflora cream
Study: 26266260
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole pill